|  |  |  |  |  |
| --- | --- | --- | --- | --- |
|  | **All AAV patients**  **(N=167)** | **AAV patients with AIP < 0.11 (N=115)** | **AAV patients with**  **AIP ≥ 0.11 (N=52)** | ***P*-value** |
| **Medications administered during**  **follow-up (N, (%))** |  |  |  |  |
| Glucocorticoid | 155 (92.8) | 104 (90.4) | 51 (98.1) | 0.107 |
| Cyclophosphamide | 87 (52.1) | 54 (47.0) | 33 (63.5) | 0.048 |
| Rituximab | 29 (17.4) | 15 (13.0) | 14 (26.9) | 0.028 |
| Azathioprine | 82 (49.1) | 52 (45.2) | 30 (57.7) | 0.135 |
| Mycophenolate mofetil | 22 (13.2) | 13 (11.3) | 9 (17.3) | 0.288 |
| Tacrolimus | 11 (6.6) | 6 (5.2) | 5 (9.6) | 0.289 |
| Methotrexate | 12 (7.2) | 10 (8.7) | 2 (3.8) | 0.345 |

**Additional File 2. Comparison of medication usage between patients with AIP ≥ 0.11 and AIP < 0.11 during follow-up**

AIP: atherogenic index of plasma; AAV: ANCA-associated vasculitis; ANCA: antineutrophil cytoplasmic antibody.